BC Week In Review | Sep 8, 2014
Company News

Photocure, Salix deal

Photocure said it and Salix mutually agreed to terminate a 2010 deal granting Salix exclusive, worldwide rights, excluding the Nordic region, to develop and commercialize Lumacan hexaminolevulinate. Photocure will receive $5 million from Salix and...
BC Week In Review | Jan 13, 2014
Clinical News

Cevira regulatory update

Photocure said FDA denied the company's request to grant Fast Track designation to Cevira to treat HPV infection in women with cervical intraepithelial neoplasia (CIN) grade 2. Photocure said FDA's decision is based on a...
BC Week In Review | Dec 9, 2013
Clinical News

Cysview regulatory update

Photocure announced that Centers for Medicare & Medicaid Services (CMS) issued a final rule creating a new package category for bladder cancer diagnostic Cysview hexaminolevulinate next year. The company said that the ruling will result...
BC Week In Review | Nov 4, 2013
Company News

Galderma, Photocure deal

Photocure said it amended an October 2009 deal with Galderma to allow Photocure to partner with another company for development and commercialization of Visonac prior to Phase III testing. Under the amendment, Photocure will make...
BC Week In Review | Apr 15, 2013
Clinical News

Cevira: Final Phase IIb data

Final data from a double-blind, international Phase IIb trial in 262 patients with cervical intraepithelial neoplasia (CIN) 1/2 showed that 5% intravaginal Cevira improved the 6-month disease clearance rate of HPV types 16 and 18...
BC Week In Review | Apr 8, 2013
Clinical News

Cysview hexaminolevulinate regulatory update

Photocure said the European Association of Urology updated guidelines on non-muscle-invasive bladder cancer recommending the use of photodynamic diagnosis in patients who are suspected of having a high-grade tumor. Photocure said the updated guidelines "strengthen"...
BC Week In Review | Jan 7, 2013
Company News

Photocure, Salix deal

Photocure received a $4.5 million milestone payment from Salix under a 2010 deal granting Salix exclusive, worldwide rights, excluding the Nordic region, to develop and commercialize Lumacan hexaminolevulinate. The milestone was triggered by an undisclosed...
BC Week In Review | Dec 24, 2012
Clinical News

Cevira: Phase IIb data

A double-blind, international Phase IIb trial in 262 patients with cervical intraepithelial neoplasia (CIN) 1/2 showed that 5% intravaginal Cevira non-significantly improved the 3-month disease clearance rate (73% vs. 60%, p=0.2) and the clearance rate...
BC Week In Review | Oct 8, 2012
Company News

Photocure dermatology news

Photocure said it will exit its Allumera cosmetic dermatology business in the U.S. by the end of this year because the business has not delivered the growth potential it had expected. In June 2011, Photocure...
BC Week In Review | Jul 9, 2012
Company News

Photocure management update

Photocure ASA (OSE:PHO), Oslo, Norway   Business: Cancer, Dermatology   Hired: Erik Dahl as CFO, effective Aug. 15, formerly CFO of GET A/S; he replaces Interim CFO Torbjorn Oye  ...
Items per page:
1 - 10 of 197
BC Week In Review | Sep 8, 2014
Company News

Photocure, Salix deal

Photocure said it and Salix mutually agreed to terminate a 2010 deal granting Salix exclusive, worldwide rights, excluding the Nordic region, to develop and commercialize Lumacan hexaminolevulinate. Photocure will receive $5 million from Salix and...
BC Week In Review | Jan 13, 2014
Clinical News

Cevira regulatory update

Photocure said FDA denied the company's request to grant Fast Track designation to Cevira to treat HPV infection in women with cervical intraepithelial neoplasia (CIN) grade 2. Photocure said FDA's decision is based on a...
BC Week In Review | Dec 9, 2013
Clinical News

Cysview regulatory update

Photocure announced that Centers for Medicare & Medicaid Services (CMS) issued a final rule creating a new package category for bladder cancer diagnostic Cysview hexaminolevulinate next year. The company said that the ruling will result...
BC Week In Review | Nov 4, 2013
Company News

Galderma, Photocure deal

Photocure said it amended an October 2009 deal with Galderma to allow Photocure to partner with another company for development and commercialization of Visonac prior to Phase III testing. Under the amendment, Photocure will make...
BC Week In Review | Apr 15, 2013
Clinical News

Cevira: Final Phase IIb data

Final data from a double-blind, international Phase IIb trial in 262 patients with cervical intraepithelial neoplasia (CIN) 1/2 showed that 5% intravaginal Cevira improved the 6-month disease clearance rate of HPV types 16 and 18...
BC Week In Review | Apr 8, 2013
Clinical News

Cysview hexaminolevulinate regulatory update

Photocure said the European Association of Urology updated guidelines on non-muscle-invasive bladder cancer recommending the use of photodynamic diagnosis in patients who are suspected of having a high-grade tumor. Photocure said the updated guidelines "strengthen"...
BC Week In Review | Jan 7, 2013
Company News

Photocure, Salix deal

Photocure received a $4.5 million milestone payment from Salix under a 2010 deal granting Salix exclusive, worldwide rights, excluding the Nordic region, to develop and commercialize Lumacan hexaminolevulinate. The milestone was triggered by an undisclosed...
BC Week In Review | Dec 24, 2012
Clinical News

Cevira: Phase IIb data

A double-blind, international Phase IIb trial in 262 patients with cervical intraepithelial neoplasia (CIN) 1/2 showed that 5% intravaginal Cevira non-significantly improved the 3-month disease clearance rate (73% vs. 60%, p=0.2) and the clearance rate...
BC Week In Review | Oct 8, 2012
Company News

Photocure dermatology news

Photocure said it will exit its Allumera cosmetic dermatology business in the U.S. by the end of this year because the business has not delivered the growth potential it had expected. In June 2011, Photocure...
BC Week In Review | Jul 9, 2012
Company News

Photocure management update

Photocure ASA (OSE:PHO), Oslo, Norway   Business: Cancer, Dermatology   Hired: Erik Dahl as CFO, effective Aug. 15, formerly CFO of GET A/S; he replaces Interim CFO Torbjorn Oye  ...
Items per page:
1 - 10 of 197